In a recent entry for “re:Cycling,” the blog of the Society for Menstrual Cycle Research, journalist Holly Grigg-Spall questions whether the U.S. Food and Drug Administration went far enough in its new labeling requirements for the Yasmin line of birth control pills.
Grigg-Spall points out that the new labels mention the results of “conflicting” studies, most of which concluded that the pills in question cause a significant increase ...
continue reading...